Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial save search
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
AEZS | $1.97 0.73% 6K
|
Health Technology
|
| O: -1.5%
H: 6.09%
C: 5.58%
year ongoing financial results growth hormone
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published: 2024-03-27 (Crawled : 12:00) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
MRNA S | $103.81 -0.05% -0.05% 2.2M
|
Health Technology
|
| O: 2.02%
H: 1.41%
C: 0.92%
vaccine trials
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
PMVP | $1.595 -2.45% -2.51% 330K
|
Commercial Services
|
| O: -1.2%
H: 4.27%
C: 0.61%
tp53 first tumors pharmaceuticals global trial
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
AVIR | $3.74 -0.53% -0.53% 130K
|
Health Technology
|
| O: 3.71%
H: 3.45%
C: 2.3%
covid-19 bemnifosbuvir antiviral pharmaceuticals global trial
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
Published: 2024-03-26 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.77 -0.31% -0.31% 190K
|
n/a
|
| O: 1.22%
H: 3.11%
C: 2.59%
kp1077 trial therapeutics
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
MEIP | $3.2 -1.54% -1.56% 16K
|
Health Technology
|
| O: -1.08%
H: 1.9%
C: 0.78%
pharma update leukemia study
Global $4.1 Billion Clinical Trial Supplies Market Report 2024-2034 - Emerging Markets Catalyzing Growth in Clinical Trial Supplies
Published: 2024-03-26 (Crawled : 17:00) - prnewswire.com
JNJ | $144.45 -2.13% 0.03% 13M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ICLR | $293.91 -1.74% -1.77% 650K
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.43%
report global trial growth market
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Published: 2024-03-26 (Crawled : 12:30) - globenewswire.com
INZY | $4.855 3.08% 2.99% 700K
|
Health Technology
|
| O: 2.09%
H: 14.47%
C: 6.6%
inz-701 pharma report ongoing trials topline
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
RVPH | $3.33 -4.31% -4.5% 93K
|
|
| O: 1.91%
H: 27.19%
C: 19.69%
brilaroxazine meeting schizophrenia trial
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA S | $103.81 -0.05% -0.05% 2.2M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Published: 2024-03-26 (Crawled : 11:00) - prnewswire.com
VKTX | $67.94 1.48% 1.46% 2.1M
|
Health Technology
|
| O: 12.02%
H: 14.95%
C: 4.28%
LGND | $80.01 0.3% 0.3% 160K
|
Health Technology
|
| O: 0.82%
H: 0.62%
C: -1.69%
vk2735 agonist trial therapeutics results
United States Food & Drug Administration Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease
Published: 2024-03-26 (Crawled : 07:00) - biospace.com/
MESO | $4.71 -8.9% -9.77% 470K
|
Health Technology
|
| O: 23.18%
H: 0.0%
C: 0.0%
drug disease children food trial submission
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
DVAX | $11.5 -1.63% -1.65% 2M
|
Health Technology
|
| O: 0.72%
H: 0.4%
C: -1.75%
candidate vaccine valneva trial
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Published: 2024-03-26 (Crawled : 03:00) - globenewswire.com
MESO | $4.71 -8.9% -9.77% 470K
|
Health Technology
|
| O: 23.18%
H: 0.0%
C: 0.0%
drug disease children food trial submission
Translational Vision Science and Technology Journal Publishes RadiusXR's NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry
Published: 2024-03-25 (Crawled : 00:00) - biospace.com/
GKOS M | $96.95 0.11% 0.0% 430K
|
Health Technology
|
| O: 0.73%
H: 2.38%
C: 0.0%
innovation vision technology
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Published: 2024-03-25 (Crawled : 21:00) - globenewswire.com
ELDN | $1.64 -4.32% 17K
|
Manufacturing
|
| O: -1.45%
H: 4.9%
C: 3.92%
pharmaceuticals trial
Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-03-25 (Crawled : 16:00) - prnewswire.com
TMO | $554.55 -0.6% 0.0% 1M
|
Health Technology
|
| O: 0.02%
H: 0.31%
C: -1.65%
INFY | $17.05 -1.27% 0.0% 13M
|
Technology Services
|
| O: 0.4%
H: 0.0%
C: -0.9%
CTLT | $55.78 -0.53% 0.0% 1.3M
|
Health Technology
|
| O: 0.54%
H: 0.82%
C: 0.55%
ICLR | $293.91 -1.74% -1.77% 650K
|
Health Technology
|
| O: 0.02%
H: 0.34%
C: -0.68%
report reach trial market
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
fda cancer blood therapy
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Published: 2024-03-25 (Crawled : 15:00) - biospace.com/
SYRS | $5.54 3.55% 3.43% 290K
|
Health Technology
|
| O: -0.32%
H: 3.84%
C: 2.4%
trial
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
MBRX | $4.355 -2.35% -2.41% 16K
|
Health Technology
|
| O: 5.18%
H: 0.0%
C: -12.5%
mb-106 positive aml trial
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.